HIMS,AMRX Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: ELF LFMD PRGO TDOC GDRX AMWL DOCS CLOV RXRX TWST

| Held by: IJH VTI IWM VB VBK VXF IWO XMMO MDY IJK

Index	RUT	P/E	63.99	EPS (ttm)	0.54	Insider Own	9.29%	Shs Outstand	219.12M	Perf Week	-6.10%
Market Cap	7.88B	Forward P/E	57.85	EPS next Y	0.60	Insider Trans	-7.98%	Shs Float	206.49M	Perf Month	-0.29%
Enterprise Value	8.37B	PEG	4.72	EPS next Q	0.05	Inst Own	89.50%	Short Float	32.61%	Perf Quarter	-35.00%
Income	133.79M	P/S	3.56	EPS this Y	-11.46%	Inst Trans	14.43%	Short Ratio	2.81	Perf Half Y	-16.42%
Sales	2.21B	P/B	13.55	EPS next Y	27.49%	ROA	9.44%	Short Interest	67.33M	Perf YTD	43.13%
Book/sh	2.55	P/C	12.51	EPS next 5Y	12.25%	ROE	26.21%	52W High	72.98 -52.58%	Perf Year	31.30%
Cash/sh	2.77	P/FCF	67.87	EPS past 3/5Y	- 17.22%	ROIC	7.89%	52W Low	23.97 44.39%	Perf 3Y	411.98%
Dividend Est.	-	EV/EBITDA	48.01	Sales past 3/5Y	75.77% -	Gross Margin	65.40%	Volatility	4.98% 5.10%	Perf 5Y	179.11%
Dividend TTM	-	EV/Sales	3.78	EPS Y/Y TTM	28.15%	Oper. Margin	5.96%	ATR (14)	2.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.64	Sales Y/Y TTM	78.02%	Profit Margin	6.05%	RSI (14)	38.07	Recom	2.72
Dividend Gr. 3/5Y	- -	Current Ratio	1.88	EPS Q/Q	-80.29%	SMA20	-7.12%	Beta	2.36	Target Price	46.91
Payout	0.00%	Debt/Eq	1.92	Sales Q/Q	49.16%	SMA50	-16.32%	Rel Volume	0.34	Prev Close	35.05
Employees	1637	LT Debt/Eq	1.92	Earnings	Nov 03 AMC	SMA200	-24.38%	Avg Volume	23.95M	Price	34.61
IPO	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-36.37% 3.23%	Trades		Volume	7,809,663	Change	-1.26%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$48
Oct-21-25	Initiated	KeyBanc Capital Markets	Sector Weight
Jun-23-25	Downgrade	Needham	Buy → Hold
Jun-04-25	Reiterated	Needham	Buy	$61 → $65
Apr-29-25	Downgrade	TD Cowen	Buy → Hold	$30
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$42 → $60
Jan-10-25	Downgrade	Citigroup	Neutral → Sell	$24 → $25
Jan-07-25	Initiated	BTIG Research	Buy	$35
Dec-17-24	Initiated	Morgan Stanley	Overweight	$42
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy	$24
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral	$16 → $20
Apr-16-24	Downgrade	Jefferies	Buy → Hold	$17 → $15
Apr-10-24	Initiated	Canaccord Genuity	Buy	$20
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform	$16
Feb-26-24	Initiated	Leerink Partners	Market Perform	$10
Dec-07-23	Initiated	Imperial Capital	In-line	$9
Jul-28-23	Initiated	TD Cowen	Outperform	$11
Apr-11-23	Initiated	Robert W. Baird	Neutral	$10

Show Previous Ratings

Today 02:08PM	3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run (Zacks)
11:45AM	Hims & Hers Expands Subscription-Led Care as Platform Engagement Grows (Zacks)
09:00AM	Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Dec-19-25 08:51AM	2 Top Stocks to Buy With $500 Right Now (Motley Fool)
07:36AM	Tempus AI Approaching Profitability Despite GAAP Losses (Zacks)
09:08AM	Loading…
Dec-18-25 09:08AM	3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026 (Zacks)
Dec-17-25 02:00PM	Telehealth company Hims & Hers investing $200 million in New Albany (The Columbus Dispatch) -5.13%
09:33AM	3 Stocks High on My Watch List to Buy (Motley Fool)
Dec-16-25 12:11PM	Hims & Hers Scales Technology-Driven Care as Profitability Evolves (Zacks)
Dec-12-25 09:38AM	Hims & Hers Expands Weight-Management Program to the United Kingdom (Zacks)
09:00AM	Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know (Zacks)
Dec-11-25 10:32AM	Hims & Hers Expands Its Technology-Driven Personalized Virtual Care (Zacks)
01:15AM	Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened (Bloomberg)
Dec-10-25 04:15PM	Hims stock falls after lawmakers propose GLP-1 compounding restrictions (Investing.com)
07:37AM	Is TEM Stock a Buy, Hold, or Sell During Its Pivotal Transition? (Zacks)
06:34AM	Loading…
06:34AM	Hims & Hers Expands Weight Loss Program to the U.K. (GuruFocus.com)
03:30AM	Hims & Hers Brings Comprehensive Weight Loss Programme to the UK (Business Wire)
Dec-09-25 11:25AM	Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell? (Zacks)
09:32AM	5 High Short-Interest Stocks to Buy Before Q1 2026 (MarketBeat)
Dec-08-25 11:40AM	OMCL vs. HIMS: Which Stock Should Value Investors Buy Now? (Zacks)
Dec-05-25 08:44AM	Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves (Zacks)
07:59AM	Wegovy's prices are going down, but they are 'wildly different' (MarketWatch)
Dec-04-25 11:39PM	2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm (StockStory) +7.96%
04:18PM	Stocks to Watch Thursday: Salesforce, Meta, Kroger, Dollar General (The Wall Street Journal)
11:46AM	HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency (Zacks)
11:41AM	Hims & Hers Targets Canadian Obesity Crisis in Bold Weight-Loss Push with Semaglutide Tailwind (GuruFocus.com)
11:16AM	Hims & Hers Health, Inc. (HIMS): A Bull Case Theory (Insider Monkey)
11:06AM	Hims & Hers Stock Gains on Move Into Canada (The Wall Street Journal)
10:15AM	The Three Moves Hims & Hers Made This Week To Bolster Its Weight-Loss Biz (Investor's Business Daily)
07:00AM	Hims & Hers Now Serving Customers in Canada (Business Wire)
07:00AM	Loading…
07:00AM	Hims & Hers Continues Major International Expansion With Official Entry Into Canada (Business Wire)
04:59AM	Hims & Hers Health signs agreement to acquire YourBio Health (Medical Device Network)
Dec-03-25 11:30AM	Hims & Hers Health (HIMS) Down 15.1% Since Last Earnings Report: Can It Rebound? (Zacks)
10:28AM	Hims & Hers Expands Care Scope as Prescription Platforms Evolve (Zacks)
09:00AM	Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology (Business Wire)
Dec-01-25 09:00AM	Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock (Zacks) -5.66%
Nov-28-25 12:38PM	HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside? (Zacks)
Nov-25-25 12:28PM	Hims & Hers Expands Care Scope as Digital Health Platforms Evolve (Zacks)
Nov-24-25 05:32PM	Hims, Block, and NRG Just Launched Huge Stock Buybacks (MarketBeat) +8.84%
Nov-23-25 11:33PM	1 Small-Cap Stock with Exciting Potential and 2 We Avoid (StockStory)
Nov-22-25 07:00AM	MarketBeat Week in Review - 11/17 - 11/21 (MarketBeat)
Nov-21-25 10:54AM	Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model (Zacks)
Nov-20-25 11:40AM	OMCL or HIMS: Which Is the Better Value Stock Right Now? (Zacks) -6.17%
Nov-19-25 05:27PM	HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? (MarketBeat)
Nov-18-25 11:43AM	Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell? (Zacks)
09:00AM	Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? (Zacks)
Nov-17-25 04:44PM	How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration (Investor's Business Daily)
02:11PM	Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today (StockStory)
08:56AM	Novo Nordisk Cuts Prices for Obesity Drugs (The Wall Street Journal)
08:00AM	Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization (Business Wire)
06:00AM	Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy (Business Wire)
Nov-13-25 11:40PM	1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds (StockStory) -7.61%
12:00PM	Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys (Business Wire)
11:49AM	Hims & Hers Bets on Lab Testing to Boost Growth (The Wall Street Journal)
08:15AM	2 Strong Healthcare Stock Picks for Growth Investors (Motley Fool)
04:40AM	2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors (Motley Fool)
Nov-12-25 08:39AM	Huge Opportunity to Buy These 4 Stocks (Motley Fool)
06:55AM	Consumer discretionary is the most-shorted sector amid concern about the U.S. economy (MarketWatch)
Nov-11-25 10:31PM	Healthcare Technology Stocks Q3 Teardown: Hims & Hers Health (NYSE:HIMS) Vs The Rest (StockStory)
12:43PM	Hims & Hers Scales Technology-Enabled, Vertically Integrated Care (Zacks)
05:30AM	Obesity Drugs Are About to Go Mass-Market (The Wall Street Journal)
Nov-10-25 12:31AM	Hims & Hers Health's Q3 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Nov-09-25 04:35AM	Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? (Motley Fool)
Nov-07-25 12:43PM	Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care (Zacks)
09:00AM	Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? (Zacks)
08:02AM	The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. (Investor's Business Daily)
Nov-05-25 04:31PM	Novo Nordisk CFO On Metsera, Hims And Lilly, And Why 'Hyper Growth' Has Stalled (Investor's Business Daily) -5.05%
12:26PM	Why Are Hims & Hers Health (HIMS) Shares Soaring Today (StockStory)
12:12PM	Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract (Zacks)
10:41AM	Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results (MarketBeat)
Nov-04-25 07:11PM	Analyst Report: Hims & Hers Health, Inc. (Morningstar Research)
04:17PM	Hims Says It's Negotiating A New Deal With Novo Nordisk, But Shares Slide (Investor's Business Daily)
11:40AM	OMCL vs. HIMS: Which Stock Is the Better Value Option? (Zacks)
10:51AM	Hims & Hers Eyes Major Weight-Loss Breakthrough With Potential Novo Nordisk Wegovy Deal (GuruFocus.com)
08:46AM	HIMS Q3 Deep Dive: Personalized Offerings and Strategic Expansion Shape Telehealth Growth (StockStory)
06:41AM	Hims Shares Rise on Talks to Offer Novos New Obesity Pill (Bloomberg)
12:04AM	Hims & Hers Health Inc (HIMS) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Nov-03-25 11:14PM	Analyst Report: Hims & Hers Health, Inc. (Morningstar Research)
06:23PM	Novo Nordisk's Wegovy could soon have a new sales outlet in the U.S. (MarketWatch)
05:47PM	Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge (Investor's Business Daily)
05:45PM	Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates (Zacks)
05:38PM	Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow (The Wall Street Journal)
05:31PM	Hims and Hers revenue tops estimates amid jump in subscriber growth (Investing.com)
04:32PM	Earnings live: Palantir stock rises modestly on strong results, Hims & Hers stock surges (Yahoo Finance)
04:24PM	Hims & Hers Health's (NYSE:HIMS) Q3 Sales Top Estimates (StockStory)
04:05PM	Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results (Business Wire)
11:40AM	OMCL vs. HIMS: Which Stock Should Value Investors Buy Now? (Zacks)
11:26AM	Stock Market Today: Palantir, Vertex, and Hims & Hers Report After the Closing Bell (TheStreet)
Nov-02-25 07:40AM	Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week (Yahoo Finance)
05:30AM	Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk (The Wall Street Journal)
Nov-01-25 11:07PM	Hims & Hers Health (HIMS) Q3 Earnings: What To Expect (StockStory)
Oct-31-25 03:20PM	Why Hims & Hers Health (HIMS) Stock Is Trading Up Today (StockStory)
01:58PM	Hims & Hers Scales AI-Driven Personalized Health and Wellness (Zacks)
10:09AM	Hims & Hers Q3 Preview: Growth Faces a Confidence Test (GuruFocus.com)
Oct-29-25 01:39PM	Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings? (Zacks)
10:00AM	Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 05:45PM	Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts (Zacks)
Oct-27-25 01:50PM	HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now? (Zacks)
10:00AM	Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-24-25 06:35PM	Hims & Hers Short Interest Nears All-Time High, Buy The Dip? (MarketBeat)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oluyemi Okupe	Officer	Dec 22 '25	Proposed Sale	35.05	32,160	1,127,208		Dec 22 05:00 PM
Chi Michael	Chief Operating Officer	Dec 17 '25	Sale	36.71	13,750	504,762	305,161	Dec 18 04:15 PM
Autor Deborah M.	Chief Policy Officer	Dec 17 '25	Sale	36.71	7,054	258,952	6,175	Dec 18 04:15 PM
Carroll Patrick Harrison	Chief Medical Officer	Dec 17 '25	Sale	36.71	10,021	367,871	169,940	Dec 18 04:15 PM
Becklund Irene	PAO	Dec 17 '25	Sale	36.71	8,411	308,768	2,126	Dec 18 04:15 PM
Carroll Patrick Harrison	Officer	Dec 17 '25	Proposed Sale	36.71	10,021	367,871		Dec 17 10:26 AM
Chi Michael	Officer	Dec 17 '25	Proposed Sale	36.71	13,750	504,762		Dec 17 10:14 AM
Becklund Irene	Officer	Dec 17 '25	Proposed Sale	36.71	8,411	308,768		Dec 17 09:50 AM
Autor Deborah M.	Officer	Dec 17 '25	Proposed Sale	36.71	7,054	258,952		Dec 17 09:42 AM
Perez Garcia Andrea G	Director	Dec 09 '25	Sale	39.17	2,500	97,925	80,166	Dec 10 04:35 PM
Perez Garcia Andrea G	Director	Dec 09 '25	Proposed Sale	39.17	2,500	97,925		Dec 09 10:07 AM
Boughton Soleil	Chief Legal Officer	Nov 24 '25	Sale	35.22	2,631	92,664	153,225	Nov 25 04:13 PM
Boughton Soleil	Officer	Nov 24 '25	Proposed Sale	35.11	2,631	92,374		Nov 24 10:03 AM
Okupe Oluyemi	Chief Financial Officer	Nov 17 '25	Option Exercise	7.15	23,187	165,817	93,419	Nov 19 04:31 PM
Okupe Oluyemi	Chief Financial Officer	Nov 17 '25	Sale	36.81	23,187	853,490	70,232	Nov 19 04:31 PM
Boughton Soleil	Chief Legal Officer	Nov 10 '25	Sale	42.53	2,637	112,152	155,856	Nov 12 08:02 PM
Boughton Soleil	Officer	Nov 10 '25	Proposed Sale	42.53	2,637	112,152		Nov 10 10:16 AM
Boughton Soleil	Chief Legal Officer	Oct 27 '25	Sale	50.10	2,637	132,114	158,493	Oct 28 04:23 PM
Boughton Soleil	Officer	Oct 27 '25	Proposed Sale	50.10	2,637	132,114		Oct 27 09:42 AM
Okupe Oluyemi	Chief Financial Officer	Oct 17 '25	Option Exercise	7.15	11,592	82,898	81,824	Oct 20 04:42 PM
Okupe Oluyemi	Chief Financial Officer	Oct 17 '25	Sale	57.13	11,592	662,222	70,232	Oct 20 04:42 PM
Dudum Andrew	Officer	Oct 16 '25	Proposed Sale	62.79	175,661	11,029,998		Oct 16 03:10 PM
Chi Michael	Chief Commercial Officer	Oct 10 '25	Option Exercise	6.82	900	6,138	292,339	Oct 14 04:17 PM
Chi Michael	Chief Commercial Officer	Oct 10 '25	Sale	58.25	900	52,425	291,439	Oct 14 04:17 PM
Boughton Soleil	Chief Legal Officer	Oct 13 '25	Sale	54.38	2,637	143,400	161,130	Oct 14 04:17 PM
Boughton Soleil	Officer	Oct 13 '25	Proposed Sale	54.38	2,637	143,400		Oct 14 06:47 AM
Chi Michael	Officer	Oct 10 '25	Proposed Sale	58.25	900	52,425		Oct 10 11:26 AM
Okupe Oluyemi	Chief Financial Officer	Oct 03 '25	Option Exercise	7.15	11,595	82,919	81,827	Oct 07 04:47 PM
Okupe Oluyemi	Chief Financial Officer	Oct 03 '25	Sale	57.72	11,595	669,232	70,232	Oct 07 04:47 PM
Chi Michael	Chief Commercial Officer	Oct 01 '25	Option Exercise	11.53	250	2,882	291,689	Oct 02 04:10 PM
Chi Michael	Chief Commercial Officer	Oct 01 '25	Sale	56.00	250	14,000	291,439	Oct 02 04:10 PM
Chi Michael	Officer	Oct 01 '25	Proposed Sale	56.00	250	14,000		Oct 01 11:34 AM
Okupe Oluyemi	Chief Financial Officer	Sep 29 '25	Option Exercise	5.01	49,832	249,658	155,232	Sep 30 04:33 PM
Okupe Oluyemi	Chief Financial Officer	Sep 29 '25	Sale	60.20	85,000	5,116,924	70,232	Sep 30 04:33 PM
Boughton Soleil	Chief Legal Officer	Sep 29 '25	Sale	58.79	2,637	155,029	163,767	Sep 30 04:33 PM
Boughton Soleil	Officer	Sep 29 '25	Proposed Sale	58.79	2,637	155,029		Sep 29 09:51 AM
Chi Michael	Chief Commercial Officer	Sep 24 '25	Option Exercise	5.01	2,100	10,521	293,539	Sep 25 06:06 PM
Chi Michael	Chief Commercial Officer	Sep 24 '25	Sale	56.52	2,100	118,692	291,439	Sep 25 06:06 PM
Okupe Oluyemi	Chief Financial Officer	Sep 22 '25	Sale	57.74	23,584	1,361,766	105,400	Sep 24 04:22 PM
Chi Michael	Officer	Sep 24 '25	Proposed Sale	56.52	2,100	118,692		Sep 24 11:02 AM
Oluyemi Okupe	Officer	Sep 22 '25	Proposed Sale	57.70	154,958	8,941,077		Sep 22 05:39 PM
Boughton Soleil	Chief Legal Officer	Sep 17 '25	Sale	50.50	2,637	133,168	166,404	Sep 19 04:28 PM
Carroll Patrick Harrison	Chief Medical Officer	Sep 17 '25	Sale	50.50	10,021	506,060	169,940	Sep 19 04:28 PM
Becklund Irene	PAO	Sep 17 '25	Sale	50.50	8,410	424,705	1,418	Sep 19 04:28 PM
Chi Michael	Chief Commercial Officer	Sep 17 '25	Sale	50.50	13,749	694,324	297,139	Sep 19 04:27 PM
Dudum Andrew	Chief Executive Officer	Sep 17 '25	Sale	50.57	65,110	3,292,906	95,315	Sep 19 04:27 PM
Chi Michael	Chief Commercial Officer	Sep 15 '25	Option Exercise	6.19	4,150	25,680	282,804	Sep 17 07:24 PM
Chi Michael	Chief Commercial Officer	Sep 15 '25	Sale	56.00	4,150	232,400	278,654	Sep 17 07:24 PM
Dudum Andrew	Chief Executive Officer	Sep 16 '25	Option Exercise	2.43	125,335	304,564	268,759	Sep 17 07:24 PM
Dudum Andrew	Chief Executive Officer	Sep 16 '25	Sale	53.48	128,127	6,852,300	160,425	Sep 17 07:24 PM
Dudum Andrew	Chief Executive Officer	Sep 16 '25	Sale	53.27	47,534	2,532,325	95,058	Sep 17 07:24 PM
Okupe Oluyemi	Chief Financial Officer	Sep 15 '25	Option Exercise	5.01	110,000	551,100	273,984	Sep 17 07:24 PM
Okupe Oluyemi	Chief Financial Officer	Sep 15 '25	Sale	55.35	145,000	8,026,076	128,984	Sep 17 07:24 PM
Dudum Andrew	Officer	Sep 17 '25	Proposed Sale	50.57	65,110	3,292,904		Sep 17 12:44 PM
Boughton Soleil	Officer	Sep 17 '25	Proposed Sale	50.50	2,637	133,168		Sep 17 11:15 AM
Carroll Patrick Harrison	Officer	Sep 17 '25	Proposed Sale	50.50	10,021	506,060		Sep 17 10:20 AM
Chi Michael	Officer	Sep 17 '25	Proposed Sale	50.50	13,749	694,324		Sep 17 10:07 AM
Becklund Irene	Officer	Sep 17 '25	Proposed Sale	50.50	8,410	424,705		Sep 17 09:50 AM
Dudum Andrew	Officer	Sep 16 '25	Proposed Sale	53.42	175,661	9,384,626		Sep 16 11:29 AM
Oluyemi Okupe	Officer	Sep 15 '25	Proposed Sale	53.96	145,000	7,824,200		Sep 15 06:35 PM
Chi Michael	Officer	Sep 15 '25	Proposed Sale	56.00	4,150	232,400		Sep 15 11:49 AM
Okupe Oluyemi	Chief Financial Officer	Aug 26 '25	Option Exercise	5.01	11,581	58,021	128,387	Aug 28 04:34 PM
Okupe Oluyemi	Chief Financial Officer	Aug 26 '25	Sale	43.69	11,581	505,968	116,806	Aug 28 04:34 PM
Boughton Soleil	Chief Legal Officer	Aug 25 '25	Sale	44.53	2,571	114,487	150,450	Aug 26 04:35 PM
Boughton Soleil	Officer	Aug 25 '25	Proposed Sale	44.53	2,571	114,487		Aug 25 09:46 AM
Dudum Andrew	Chief Executive Officer	Aug 18 '25	Option Exercise	2.43	125,335	304,564	197,855	Aug 20 04:14 PM
Dudum Andrew	Chief Executive Officer	Aug 18 '25	Sale	45.06	128,127	5,773,242	89,521	Aug 20 04:14 PM
Dudum Andrew	Chief Executive Officer	Aug 18 '25	Sale	45.05	47,534	2,141,492	142,592	Aug 20 04:14 PM
Dudum Andrew	Officer	Aug 18 '25	Proposed Sale	45.05	47,534	2,141,494		Aug 18 12:33 PM
Dudum Andrew	Officer	Aug 18 '25	Proposed Sale	45.22	128,127	5,793,903		Aug 18 10:22 AM
Okupe Oluyemi	Chief Financial Officer	Aug 13 '25	Option Exercise	5.01	11,581	58,021	65,665	Aug 15 04:18 PM
Okupe Oluyemi	Chief Financial Officer	Aug 13 '25	Sale	48.05	11,581	556,420	116,806	Aug 15 04:18 PM
Melissa Baird	Officer	Aug 12 '25	Proposed Sale	47.96	33,333	1,598,651		Aug 12 05:22 PM
Boughton Soleil	Chief Legal Officer	Aug 11 '25	Sale	51.64	2,572	132,818	153,021	Aug 12 04:33 PM
Dudum Andrew	Chief Executive Officer	Aug 07 '25	Sale	50.58	660,000	33,384,120	2,214,769	Aug 11 05:07 PM
Boughton Soleil	Officer	Aug 11 '25	Proposed Sale	51.64	2,572	132,818		Aug 11 10:18 AM
Carroll Patrick Harrison	Chief Medical Officer	Aug 06 '25	Sale	53.58	60,000	3,214,878	169,940	Aug 08 04:19 PM
Carroll Patrick Harrison	Officer	Aug 06 '25	Proposed Sale	53.58	60,000	3,214,881		Aug 06 01:27 PM
Chi Michael	Chief Commercial Officer	Jul 31 '25	Option Exercise	7.09	26,350	186,830	305,004	Aug 04 04:21 PM
Chi Michael	Chief Commercial Officer	Aug 01 '25	Option Exercise	11.53	250	2,882	278,904	Aug 04 04:21 PM
Chi Michael	Chief Commercial Officer	Jul 31 '25	Sale	67.00	26,350	1,765,450	278,654	Aug 04 04:21 PM
Chi Michael	Chief Commercial Officer	Aug 01 '25	Sale	64.44	250	16,110	278,654	Aug 04 04:21 PM
Chi Michael	Officer	Aug 01 '25	Proposed Sale	64.44	250	16,110		Aug 01 11:12 AM
Chi Michael	Officer	Jul 31 '25	Proposed Sale	67.00	26,350	1,765,450		Jul 31 11:02 AM
Boughton Soleil	Chief Legal Officer	Jul 28 '25	Sale	58.70	2,572	150,976	155,593	Jul 29 04:25 PM
Boughton Soleil	Officer	Jul 28 '25	Proposed Sale	58.70	2,572	150,976		Jul 28 12:59 PM
Chi Michael	Chief Commercial Officer	Jul 23 '25	Option Exercise	5.25	13,750	72,146	292,404	Jul 25 05:20 PM
Chi Michael	Chief Commercial Officer	Jul 24 '25	Option Exercise	5.01	2,100	10,521	280,754	Jul 25 05:20 PM
Chi Michael	Chief Commercial Officer	Jul 23 '25	Sale	56.00	13,750	770,000	278,654	Jul 25 05:20 PM
Chi Michael	Chief Commercial Officer	Jul 24 '25	Sale	57.52	2,100	120,792	278,654	Jul 25 05:20 PM
Chi Michael	Officer	Jul 24 '25	Proposed Sale	57.52	2,100	120,792		Jul 24 10:44 AM
Dudum Andrew	Chief Executive Officer	Jul 21 '25	Option Exercise	2.43	125,335	304,564	142,313	Jul 23 04:12 PM
Dudum Andrew	Chief Executive Officer	Jul 21 '25	Sale	49.54	125,335	6,208,637	92,313	Jul 23 04:12 PM
Chi Michael	Officer	Jul 23 '25	Proposed Sale	56.00	13,750	770,000		Jul 23 12:19 PM
Melissa Baird	Officer	Jul 21 '25	Proposed Sale	47.60	33,333	1,586,651		Jul 21 04:59 PM
Dudum Andrew	Officer	Jul 21 '25	Proposed Sale	49.54	125,335	6,208,636		Jul 21 10:41 AM
Dudum Andrew	Chief Executive Officer	Jul 16 '25	Sale	50.25	47,534	2,388,817	190,126	Jul 18 04:29 PM
Dudum Andrew	Chief Executive Officer	Jul 16 '25	Sale	50.58	2,792	141,217	92,313	Jul 18 04:29 PM
Dudum Andrew	Officer	Jul 16 '25	Proposed Sale	50.27	50,326	2,530,033		Jul 16 11:49 AM
Boughton Soleil	Chief Legal Officer	Jul 14 '25	Sale	47.82	2,572	122,993	158,165	Jul 15 04:28 PM

AMRX Amneal Pharmaceuticals Inc daily Stock Chart

Peers: JNJ PFE NVS TAK TEVA PRGO FMS RDY SNN

| Held by: VTI VB IWM VBR VXF IWO DFAS SCHA PJP VTWO

Index	RUT	P/E	902.82	EPS (ttm)	0.01	Insider Own	50.13%	Shs Outstand	314.31M	Perf Week	5.34%
Market Cap	4.03B	Forward P/E	13.84	EPS next Y	0.93	Insider Trans	-0.81%	Shs Float	156.78M	Perf Month	7.28%
Enterprise Value	6.55B	PEG	0.55	EPS next Q	0.18	Inst Own	44.16%	Short Float	3.90%	Perf Quarter	32.03%
Income	5.90M	P/S	1.37	EPS this Y	37.67%	Inst Trans	4.75%	Short Ratio	3.43	Perf Half Y	59.25%
Sales	2.93B	P/B	-	EPS next Y	16.04%	ROA	0.17%	Short Interest	6.12M	Perf YTD	61.87%
Book/sh	-0.35	P/C	17.08	EPS next 5Y	25.02%	ROE	-155.38%	52W High	12.84 -0.16%	Perf Year	65.42%
Cash/sh	0.75	P/FCF	16.15	EPS past 3/5Y	- 32.70%	ROIC	0.23%	52W Low	6.68 91.77%	Perf 3Y	474.89%
Dividend Est.	-	EV/EBITDA	10.83	Sales past 3/5Y	10.10% 11.43%	Gross Margin	36.76%	Volatility	2.67% 2.73%	Perf 5Y	179.91%
Dividend TTM	-	EV/Sales	2.23	EPS Y/Y TTM	102.62%	Oper. Margin	12.41%	ATR (14)	0.32	Perf 10Y	-69.34%
Dividend Ex-Date	-	Quick Ratio	1.42	Sales Y/Y TTM	9.50%	Profit Margin	0.20%	RSI (14)	65.25	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	2.13	EPS Q/Q	1560.00%	SMA20	4.05%	Beta	1.35	Target Price	14.00
Payout	-	Debt/Eq	-	Sales Q/Q	11.68%	SMA50	11.39%	Rel Volume	0.85	Prev Close	12.82
Employees	8300	LT Debt/Eq	-	Earnings	Oct 30 BMO	SMA200	39.38%	Avg Volume	1.79M	Price	12.82
IPO	Dec 19, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.92% 1.38%	Trades		Volume	1,443,888	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$15
Jun-06-25	Initiated	Goldman	Buy	$12
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight	$9 → $12
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral	$9
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform	$5
Mar-08-21	Upgrade	Goldman	Sell → Buy	$4 → $6.50
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy	$5.50
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight	$4.50 → $6
Jul-27-20	Initiated	Goldman	Sell	$4
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$11 → $5
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11 → $6
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight	$9
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy	$13
Mar-20-19	Initiated	SunTrust	Buy	$16
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$16 → $12

Show Previous Ratings

Dec-22-25 04:01PM	Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (GlobeNewswire)
04:00PM	mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA (PR Newswire)
Dec-09-25 04:01PM	Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals (GlobeNewswire)
Dec-05-25 08:00AM	Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson's Disease (GlobeNewswire)
Dec-02-25 08:00AM	Amneal to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Loading…
08:00AM	Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol (GlobeNewswire)
Dec-01-25 04:01PM	Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% (GlobeNewswire)
Nov-28-25 10:56AM	ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 10:33PM	Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)
Nov-14-25 08:44AM	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
05:10AM	Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat (Insider Monkey)
Nov-13-25 04:01PM	Amneal Receives U.S. FDA Approval for Iohexol Injection (GlobeNewswire)
Nov-11-25 11:35PM	3 Stocks Under $50 We Steer Clear Of (StockStory)
Nov-04-25 09:33AM	Implied Volatility Surging for Amneal Pharmaceuticals Stock Options (Zacks)
01:00PM	Loading…
Oct-31-25 01:00PM	Why Amneal (AMRX) Stock Is Up Today (StockStory) +8.20%
Oct-30-25 04:30PM	Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:30AM	Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:15AM	Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:47AM	Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars (StockStory)
06:14AM	Amneal: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Amneal Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-29-25 04:05PM	Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (GlobeNewswire)
09:39AM	What To Expect From Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 11:17PM	Amneal Earnings: What To Look For From AMRX (StockStory)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Amneal Launches Brekiya - the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches (GlobeNewswire)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-21-25 10:42PM	Amneal Pharmaceuticals, Inc. (AMRX): A Bull Case Theory (Insider Monkey)
09:40AM	Loading…
Oct-07-25 09:40AM	Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? (Zacks)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
08:00AM	Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR (omalizumab) (Business Wire)
Oct-03-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Oct-01-25 01:44PM	Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR Biosimilar, Targets Multi-Billion-Dollar Market (Insider Monkey)
Sep-30-25 04:05PM	Amneal to Report Third Quarter 2025 Results on October 30, 2025 (GlobeNewswire)
Sep-26-25 08:00AM	Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab) (GlobeNewswire)
Sep-23-25 08:00AM	Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% (GlobeNewswire)
Sep-15-25 05:29AM	Amneal secures FDA approval for sodium oxybate solution (Pharmaceutical Technology)
Sep-11-25 02:16PM	Why Amneal (AMRX) Stock Is Up Today (StockStory)
08:00AM	Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution (GlobeNewswire)
Sep-04-25 04:01PM	Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension (GlobeNewswire)
Sep-01-25 09:55AM	Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet (Zacks)
Aug-25-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out? (Zacks)
Aug-14-25 09:55AM	Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High? (Zacks)
Aug-13-25 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
08:50AM	Here's Why Momentum in Amneal (AMRX) Should Keep going (Zacks)
12:09AM	AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance (StockStory)
Aug-12-25 11:52PM	5 Revealing Analyst Questions From Amneal's Q2 Earnings Call (StockStory)
Aug-05-25 09:30AM	Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:30AM	Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico (GlobeNewswire)
07:15AM	Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates (Zacks)
06:16AM	Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets (StockStory)
06:14AM	Amneal: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Amneal Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 02:07PM	Viatris Poised to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
09:51AM	Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
09:35AM	Amneal Pharmaceuticals Inc (AMRX) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-03-25 11:08PM	Amneal Earnings: What To Look For From AMRX (StockStory)
Jul-31-25 02:44PM	Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT (Insider Monkey)
Jul-29-25 12:45PM	Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
10:00AM	Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Jul-28-25 11:31PM	Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
09:40AM	Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? (Zacks)
12:04AM	2 Reasons to Avoid AMRX and 1 Stock to Buy Instead (StockStory)
Jul-21-25 07:39AM	Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 (GlobeNewswire)
07:38AM	Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-18-25 07:00AM	Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada (GlobeNewswire)
Jul-11-25 11:27AM	Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension (Insider Monkey)
Jul-09-25 08:00AM	Amneal to Report Second Quarter 2025 Results on August 5, 2025 (GlobeNewswire)
Jul-02-25 10:09PM	Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares (Insider Monkey)
Jul-01-25 07:05AM	Indivior (INDV) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-25 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
Jun-26-25 05:46PM	5 Revealing Analyst Questions From Amneal's Q1 Earnings Call (StockStory)
Jun-25-25 08:00AM	Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences (GlobeNewswire)
Jun-17-25 10:00AM	Generic Drugmakers Resist Trumps Calls for More U.S. Manufacturing (The Wall Street Journal)
Jun-13-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
Jun-12-25 08:00AM	Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension (GlobeNewswire)
Jun-10-25 09:15AM	Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jun-04-25 09:55AM	Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade (Zacks)
May-29-25 04:05PM	Amneal to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-26-25 12:45PM	3 Reasons Growth Investors Will Love Amneal (AMRX) (Zacks)
May-16-25 09:11AM	AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress (StockStory)
May-15-25 08:00AM	Amneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults (GlobeNewswire)
May-09-25 09:55AM	Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? (Zacks)
May-08-25 12:45PM	Here is Why Growth Investors Should Buy Amneal (AMRX) Now (Zacks)
08:34AM	Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? (Zacks)
07:00AM	Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. (GlobeNewswire)
12:35AM	3 Value Stocks in Hot Water (StockStory)
May-07-25 12:31AM	3 Small-Cap Stocks Facing Headwinds (StockStory)
May-03-25 03:03AM	Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ... (GuruFocus.com)
May-02-25 11:32AM	Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates (Zacks)
06:00AM	Amneal Reports First Quarter 2025 Financial Results (Business Wire)
May-01-25 09:23AM	Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nark Ted C	Director	Nov 17 '25	Sale	11.72	50,000	586,000	291,029	Nov 19 04:21 PM
Nark Ted C	Director	Nov 17 '25	Proposed Sale	11.82	50,000	591,250		Nov 17 03:06 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Option Exercise	2.75	131,856	362,604	278,259	Nov 14 05:13 PM
Shah Nikita	Executive Vice President	Nov 12 '25	Sale	11.92	131,856	1,571,724	146,403	Nov 14 05:13 PM
NIKITA SHAH	OFFICER	Nov 12 '25	Proposed Sale	11.92	131,856	1,571,723		Nov 12 05:12 PM
Kiely John	Director	Aug 27 '25	Sale	9.23	32,000	295,360	225,433	Aug 28 04:25 PM
Kiely John	Director	Aug 27 '25	Proposed Sale	9.18	32,000	293,810		Aug 27 03:04 PM
Shah Nikita	Executive Vice President	Aug 22 '25	Sale	9.66	114,492	1,105,993	152,743	Aug 25 04:27 PM
Shah Nikita	Executive Vice President	Aug 25 '25	Sale	9.50	6,340	60,230	146,403	Aug 25 04:27 PM
BOYER ANDREW S	Executive Vice President	Aug 20 '25	Option Exercise	2.75	175,000	481,250	431,670	Aug 22 04:38 PM
BOYER ANDREW S	Executive Vice President	Aug 20 '25	Sale	9.38	279,244	2,619,309	152,426	Aug 22 04:38 PM
Shah Nikita	Officer	Aug 22 '25	Proposed Sale	9.70	36,796	356,921		Aug 22 04:03 PM
Shah Nikita	Officer	Aug 22 '25	Proposed Sale	9.74	84,036	818,931		Aug 22 12:18 PM
BOYER ANDREW S	Officer	Aug 20 '25	Proposed Sale	9.36	175,000	1,637,900		Aug 20 04:16 PM
BOYER ANDREW S	Officer	Aug 20 '25	Proposed Sale	9.30	104,244	969,469		Aug 20 10:26 AM
Shah Nikita	Executive Vice President	Aug 14 '25	Sale	9.29	71,694	666,037	267,235	Aug 15 04:31 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 15 '25	Sale	9.43	219,159	2,066,669	122,152	Aug 15 04:30 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 13 '25	Sale	9.22	161,365	1,487,785	460,517	Aug 15 04:30 PM
Konidaris Tasos	Executive Vice President & CFO	Aug 14 '25	Sale	9.30	119,206	1,108,616	341,311	Aug 15 04:30 PM
Konidaris Tasos	Officer	Aug 15 '25	Proposed Sale	9.39	219,159	2,057,903		Aug 15 11:14 AM
Shah Nikita	Officer	Aug 14 '25	Proposed Sale	9.25	71,694	663,065		Aug 14 04:10 PM
Shah Nikita	Executive Vice President	Aug 12 '25	Sale	9.04	50,000	452,000	338,929	Aug 13 04:40 PM
Daly Jason B.	EVP, Chief Legal Officer	Aug 12 '25	Sale	9.05	22,000	199,100	10,606	Aug 13 04:39 PM
BOYER ANDREW S	Executive Vice President	Aug 12 '25	Sale	9.05	33,436	302,596	256,670	Aug 13 04:38 PM
Konidaris Tasos	Officer	Aug 13 '25	Proposed Sale	9.27	169,206	1,568,539		Aug 13 03:08 PM
Konidaris Tasos	Officer	Aug 13 '25	Proposed Sale	9.02	111,635	1,006,947		Aug 13 10:41 AM
BOYER ANDREW S	Officer	Aug 12 '25	Proposed Sale	9.09	33,436	304,100		Aug 12 04:06 PM
Daly Jason B.	Officer	Aug 12 '25	Proposed Sale	9.00	22,000	198,000		Aug 12 04:04 PM
Shah Nikita	Officer	Aug 12 '25	Proposed Sale	9.06	50,000	453,000		Aug 12 03:09 PM
Patel Gautam	Director	Jun 16 '25	Sale	8.02	94,906	761,146	1,609,144	Jun 18 04:11 PM
Patel Gautam	Director	Jun 10 '25	Sale	8.02	56,426	452,537	1,704,050	Jun 12 04:19 PM
Shah Nikita	Executive Vice President	May 16 '25	Sale	7.58	49,140	372,481	388,929	May 19 04:16 PM
Shah Nikita	Officer	May 16 '25	Proposed Sale	7.50	49,140	368,550		May 16 04:02 PM
Kiely John	Director	May 12 '25	Sale	7.59	50,000	379,500	257,433	May 13 04:42 PM
Kiely John	Director	May 12 '25	Proposed Sale	7.57	50,000	378,500		May 12 04:07 PM
Patel Gautam	Director	May 05 '25	Sale	8.00	4,900	39,200	1,720,218	May 06 04:29 PM
Patel Gautam	Director	May 02 '25	Sale	8.00	3,768	30,144	1,725,118	May 06 04:29 PM
Gautam Patel	Director	May 02 '25	Proposed Sale	7.74	160,000	1,238,400		May 02 04:38 PM
Patel Gautam	Director	Apr 01 '25	Sale	8.30	80,000	664,000	1,728,886	Apr 02 04:12 PM
Patel Tushar Bhikhubhai	10% Owner	Mar 14 '25	Sale	8.35	5,000,000	41,750,000	48,578,209	Mar 17 04:51 PM
Patel Tushar Bhikhubhai	10% Owner	Mar 14 '25	Proposed Sale	8.75	5,000,000	43,750,000		Mar 14 07:32 PM
BOYER ANDREW S	Executive Vice President	Mar 05 '25	Sale	8.89	125,000	1,111,250	290,106	Mar 07 04:18 PM
Daly Jason B.	EVP, Chief Legal Officer	Mar 06 '25	Sale	8.73	46,936	409,751	32,606	Mar 07 04:17 PM
Daly Jason B.	EVP, Chief Legal Officer	Mar 05 '25	Sale	8.88	43,064	382,408	79,542	Mar 07 04:17 PM
Konidaris Tasos	Executive Vice President & CFO	Mar 05 '25	Sale	8.91	100,000	891,000	621,882	Mar 07 04:17 PM
Alva Emily Peterson	Director	Mar 05 '25	Sale	8.90	80,000	712,000	170,771	Mar 07 04:16 PM
Patel Gautam	Director	Mar 03 '25	Sale	8.90	80,000	712,000	1,808,886	Mar 05 07:12 PM
Alva Emily Peterson	Director	Mar 05 '25	Proposed Sale	8.87	85,000	753,950		Mar 05 05:02 PM
BOYER ANDREW S	Officer	Mar 05 '25	Proposed Sale	8.87	125,000	1,108,750		Mar 05 05:00 PM
Daly Jason B.	Officer	Mar 05 '25	Proposed Sale	8.80	90,000	792,000		Mar 05 04:57 PM
Konidaris Tasos	Officer	Mar 05 '25	Proposed Sale	8.84	100,000	884,000		Mar 05 10:00 AM
Patel Gautam	Director	Feb 03 '25	Sale	8.14	80,000	651,200	1,888,886	Feb 05 04:31 PM
Patel Gautam	Director	Jan 08 '25	Sale	8.01	62,590	501,346	1,968,886	Jan 10 04:25 PM
Patel Gautam	Director	Jan 02 '25	Sale	8.01	17,410	139,454	2,031,476	Jan 06 04:22 PM
Gautam J Patel	Director	Jan 02 '25	Proposed Sale	8.00	320,000	2,560,000		Jan 02 04:48 PM

HIMS

Hims & Hers Health Inc

AMRX

Amneal Pharmaceuticals Inc

Upgrade your FINVIZ experience